title: More on bevacizumab in hereditary hemorrhagic telangiectasia.
authors.forename: Sjoukje
authors.initials: S
authors.lastname: Oosting
authors.forename: Wouter
authors.initials: W
authors.lastname: Nagengast
authors.forename: Elisabeth
authors.initials: E
authors.lastname: de Vries
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D008297:Male; D008875:Middle Aged; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab